agre
current
evid
support
drug
suspens
also
european
coliti
organis
task
forc
suggest
whenev
possibl
pandem
initi
treatment
immunosuppress
drug
biolog
postpon
base
individu
risk
assess
howev
patient
substanti
clinic
activ
delay
initi
treatment
might
alway
possibl
metaanalysi
clinic
trial
data
includ
patient
given
antitumor
necrosi
factor
tnf
therapi
found
rel
risk
develop
opportunist
infect
ci
antitnf
therapi
compar
placebo
opportunist
infect
includ
tuberculosi
herp
simplex
infect
oral
oesophag
candidiasi
herp
zoster
viru
cytomegaloviru
epsteinbarr
viru
pool
analysi
patient
given
adalimumab
found
higher
diseas
activ
associ
significantli
increas
risk
seriou
opportunist
infect
year
furthermor
vedolizumab
humanis
monoclon
antibodi
gut
select
associ
airway
bowel
infect
although
lesser
extent
antitnf
drug
risk
opportunist
infect
seem
increas
patient
inflammatori
bowel
diseas
older
year
receiv
immunosuppress
result
increas
risk
opportunist
infect
inflammatori
bowel
diseas
guidelin
suggest
give
patient
viral
screen
start
biolog
particular
screen
includ
serolog
hepat
b
viru
hepat
c
viru
hiv
varicella
zoster
viru
patient
without
clear
histori
previou
infect
vaccin
tuberculosi
screen
combin
clinic
risk
stratif
chest
xray
releas
assay
addit
assess
histori
specif
infect
suggest
includ
herp
simplex
viru
varicella
zoster
viru
tuberculosi
immunis
statu
patient
inflammatori
bowel
diseas
might
increas
risk
infect
risk
sever
clinic
cours
might
increas
individu
chronic
diseas
immunomodulatori
treatment
furthermor
risk
induc
clinic
activ
individu
asymptomat
infect
exclud
believ
current
recommend
screen
initi
biolog
updat
least
temporarili
includ
test
view
rapid
spread
pandem
believ
physician
screen
even
patient
asymptomat
histori
highrisk
travel
contact
howev
importantli
exact
method
screen
decid
basi
local
polici
avail
healthcar
resourc
declar
compet
interest
divis
gastroenterolog
depart
surgeri
oncolog
gastroenterolog
univers
padua
padua
itali
